GlaxoSmithKline has said senior executives in China appear to have broken the law
GlaxoSmithKline (GSK) has said it expects "some impact" on its financial performance from a bribery investigation in China.
The comment came in a statement accompanying GSK's latest results.
Chief executive Andrew Witty is likely to say more when he presents the company's quarterly results later.
GSK has been accused by Chinese authorities of directing up to £320m through travel agencies to facilitate bribes to doctors and officials.
On Monday, GSK said senior executives in its China office appeared to have broken the law.
It also confirmed on Monday that the Chinese police had visited its Shanghai office last week and taken one employee away.
Several GSK employees have been detained over the last few weeks and the firm's British head of finance in China, Steve Nechelput, has been subject to a travel ban since the end of June.
Source: BBC News - Business http://www.bbc.co.uk/news/business-23430022#sa-ns_mchannel=rss&ns_source=PublicRSS20-sa
